Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.58 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513309 | 1.00 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL7708120 | 1.00 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL23650062 | 1.00 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL30091055 | 1.00 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL30689461 | 0.94 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL1040958 | 0.94 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL30200670 | 0.94 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL6834984 | 0.94 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL6900160 | 0.94 | TYMP (0.56) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL19493363 | 0.93 | TYMP (0.67) | TYMPP2RY12ADORA1P2RY2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| EP-4720286-A2 | SOD1-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4522628-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250026779-A1 | ETHYL MODIFIED RNA CAPS AND METHODS OF USE | MEDICI THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024249328-A2 | SOD1-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024238396-A1 | NMDA LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024220930-A2 | MAPT-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-117603287-A | One-pot synthesis process of 3',3' -dimeric phosphoramidite | 江苏申基生物科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116063365-A | Method for preparing oligonucleotide and nucleoside, nucleotide or oligonucleotide | 味之素株式会社 | 2023-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026779-A1 | ETHYL MODIFIED RNA CAPS AND METHODS OF USE | RNGTT, RNMT, NSUN2 | TYMP 535/4885P2RY12 3207/4885ADORA1 2145/4885 |
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | POLRMT, TARDBP, NSUN2 | TYMP 77/4885P2RY12 2099/4885ADORA1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.